Javascript must be enabled to continue!
Pharmacoeconomic Analysis of Influenza Vaccine Prophylaxis Using Trivalent Vaccine in the Conditions of Healthcare in Kazakhstan
View through CrossRef
The primary purpose: To assess the clinical and economic effectiveness of influenza vaccination with population coverage of 40% compared with the absence of vaccination and at 10% current coverage in the health system of the Republic of Kazakhstan. The secondary purpose: To carry out an assessment of clinical and economic effectiveness of influenza vaccination in schoolaged children compared with the absence of vaccination Methods. A decision-making model was developed to assess the economic and clinical effectiveness of influenza vaccination in children and adults. Pharmacoeconomic analysis of influenza vaccine prophylaxis with the use of the trivalent vaccine Grippol® plus in the healthcare environment of Kazakhstan. The creation of the model was based on the description of the influenza progression in vaccinated and unvaccinated children and adults depending on the possible variants of its progression. In addition, to calculate QALY loss, the effect of disease on a patient’s quality of life was taken into account. Results. According to the budget impact analysis results, if school-aged children are vaccinated with coverage of 80%, the total cost stands at 7 140 383 360.87 tenges. In the case of refusal of vaccination among school – aged children, the total treatment costs for children with influenza will account for 8 589 133 135,95 tenges, with expenditures increased by 1 448 749 775,08 tenges. If adults (18 years of age and older) are vaccinated and 10% of the population is covered by immunization, the total cost will be 27 791 126 613.76 and 26 848 387 939.88 tenges, respectively. In the case of non-vaccination in adults, the total costs for the treatment of influenza will be 28 105 372 838,39 tenges, which is higher by 314 246 224,63 tenges than in the case of the population’s vaccination coverage of 10%, and by 1 256 984 898,51 tenges with vaccination coverage of 40%. Conclusion. In general, children and adults’ vaccination is not only a cost-effective but also a cost-saving method of preventing influenza in the health care system of Kazakhstan. Keywords: influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults
Salidat Kairbekova National Research Center for Health Development
Title: Pharmacoeconomic Analysis of Influenza Vaccine Prophylaxis Using Trivalent Vaccine in the Conditions of Healthcare in Kazakhstan
Description:
The primary purpose: To assess the clinical and economic effectiveness of influenza vaccination with population coverage of 40% compared with the absence of vaccination and at 10% current coverage in the health system of the Republic of Kazakhstan.
The secondary purpose: To carry out an assessment of clinical and economic effectiveness of influenza vaccination in schoolaged children compared with the absence of vaccination Methods.
A decision-making model was developed to assess the economic and clinical effectiveness of influenza vaccination in children and adults.
Pharmacoeconomic analysis of influenza vaccine prophylaxis with the use of the trivalent vaccine Grippol® plus in the healthcare environment of Kazakhstan.
The creation of the model was based on the description of the influenza progression in vaccinated and unvaccinated children and adults depending on the possible variants of its progression.
In addition, to calculate QALY loss, the effect of disease on a patient’s quality of life was taken into account.
Results.
According to the budget impact analysis results, if school-aged children are vaccinated with coverage of 80%, the total cost stands at 7 140 383 360.
87 tenges.
In the case of refusal of vaccination among school – aged children, the total treatment costs for children with influenza will account for 8 589 133 135,95 tenges, with expenditures increased by 1 448 749 775,08 tenges.
If adults (18 years of age and older) are vaccinated and 10% of the population is covered by immunization, the total cost will be 27 791 126 613.
76 and 26 848 387 939.
88 tenges, respectively.
In the case of non-vaccination in adults, the total costs for the treatment of influenza will be 28 105 372 838,39 tenges, which is higher by 314 246 224,63 tenges than in the case of the population’s vaccination coverage of 10%, and by 1 256 984 898,51 tenges with vaccination coverage of 40%.
Conclusion.
In general, children and adults’ vaccination is not only a cost-effective but also a cost-saving method of preventing influenza in the health care system of Kazakhstan.
Keywords: influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults.
Related Results
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Please cite this paper as: Borders‐Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and...
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Background: Antiviral chemoprophylaxis for influenza is recommended in nursing homes to prevent transmission and severe disease among residents with higher risk of severe influenza...
1175. Influenza Vaccine Hesitancy in Hospitalized Children, Before and During the COVID-19 Pandemic
1175. Influenza Vaccine Hesitancy in Hospitalized Children, Before and During the COVID-19 Pandemic
Abstract
Background
Influenza vaccine is recommended for all children ≥6 months, yet uptake is suboptimal. We aimed to quantify ...
Peptide amphiphile micelles as a universal influenza vaccine delivery vehicle
Peptide amphiphile micelles as a universal influenza vaccine delivery vehicle
Despite a plethora of influenza vaccines and treatment options, there are millions of cases of influenza each year in the United States alone. Although increasing vaccination rates...
Burden and seasonality of medically attended influenza like illness (ILI) in Ethiopia, 2012 to 2017
Burden and seasonality of medically attended influenza like illness (ILI) in Ethiopia, 2012 to 2017
Abstract
Background
The influenza virus spreads rapidly around the world in seasonal epidemics, resulting in significant morbidity and mortality. In...
Establishing the Safety of Influenza Vaccine in Egg-Allergic Individuals
Establishing the Safety of Influenza Vaccine in Egg-Allergic Individuals
CME Educational Objectives
1.
Understand that trivalent influenza vaccine is safe for patients with egg allergy, includi...
Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis
Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis
Please cite this paper as: Savy et al. (2012) Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis. Influenza and Other Respiratory Viruses...
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
Surveillance for influenza-like illness (ILI) and laboratory-confirmed influenza in Victoria, Australia is undertaken jointly by the Victorian Infectious Diseases Reference Laborat...

